Holding(s) in Company

RNS Number : 5141C
Hikma Pharmaceuticals Plc
01 October 2018
 

TR-1: Standard form for notification of major holdings

 

LONDON, 01 October 2018 - Hikma Pharmaceuticals PLC (LSE: HIK) (DIFX: HIK)
(LEI: 549300BNS685UXH4JI75) announces as follows:

 

NOTIFICATION OF MAJOR HOLDINGS (to be sent to the relevant issuer and to the FCA in Microsoft Word format if possible)i


1a. Identity of the issuer or the underlying issuer of existing shares to which voting rights are attachedii:

Hikma Pharmaceuticals plc

1b. Please indicate if the issuer is a non-UK issuer (please mark with an "X" if appropriate)

Non-UK issuer


2. Reason for the notification (please mark the appropriate box or boxes with an "X")

An acquisition or disposal of voting rights

X

An acquisition or disposal of financial instruments


An event changing the breakdown of voting rights


Other (please specify)iii:


3. Details of person subject to the notification obligationiv

Name

The Capital Group Companies, Inc. ("CGC")

City and country of registered office (if applicable)

Los Angeles, CA 90071, USA

4. Full name of shareholder(s) (if different from 3.)v

Name


City and country of registered office (if applicable)


5. Date on which the threshold was crossed or reachedvi:

26 September 2018

6. Date on which issuer notified (DD/MM/YYYY):

28 September 2018

7. Total positions of person(s) subject to the notification obligation


% of voting rights attached to shares (total of 8. A)

% of voting rights through financial instruments
(total of 8.B 1 + 8.B 2)

Total of both in % (8.A + 8.B)

Total number of voting rights of issuervii

Resulting situation on the date on which threshold was crossed or reached

10.9955%

0.0000%

10.9955%

241,423,162

Position of previous notification (if

applicable)

11.0312%

0.0000%

11.0312%


 

 

9. Information in relation to the person subject to the notification obligation (please mark the

applicable box with an "X")

Person subject to the notification obligation is not controlled by any natural person or legal entity and does not control any other undertaking(s) holding directly or indirectly an interest in the (underlying) issuerxiii


Full chain of controlled undertakings through which the voting rights and/or the
financial instruments are effectively held starting with the ultimate controlling natural person or legal entity
xiv (please add additional rows as necessary)

X

Namexv

% of voting rights if it equals or is higher than the notifiable threshold

% of voting rights through financial instruments if it equals or is higher than the notifiable threshold

Total of both if it equals or is higher than the notifiable threshold

The Capital Group Companies, Inc.

Holdings by CG Management companies are set out below:

10.9955%

0.0000%

10.9955%

• Capital Research and Management Company1

10.9955%

0.0000%

10.9955%

EuroPacific Growth Fund ("EUPAC")2

6.3473%

0.0000%

6.3473%

1Subsidiary of The Capital Group Companies, Inc.

2Mutual fund managed by Capital Research and Management Company.

10. In case of proxy voting, please identify:

Name of the proxy holder


The number and % of voting rights held


The date until which the voting rights will be held



11. Additional informationxvi

CGC is the parent company of Capital Research and Management Company ("CRMC").  CRMC is a U.S.-based investment management company that manages the American Funds family of mutual funds.  CRMC manages equity assets for various investment companies through three divisions, Capital Research Global Investors, Capital International Investors and Capital World Investors.  CRMC in turn is the parent company of Capital Group International, Inc. ("CGII"), which in turn is the parent company of five investment management companies ("CGII management companies"): Capital Guardian Trust Company, Capital International, Inc., Capital International Limited, Capital International Sàrl and Capital International K.K.  The CGII management companies primarily serve as investment managers to institutional clients.

 

Neither CGC nor any of its affiliates own shares of Hikma Pharmaceuticals plc for its own account.  Rather, the shares reported on this Notification are owned by accounts under the discretionary investment management of one or more of the investment management companies described above.

 

 

Place of completion

Los Angeles, CA, USA

Date of completion

27 September 2018

 


This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 
END
 
 
HOLUAUKRWAARRRA
UK 100

Latest directors dealings